Skip to main content

Table 2 Treatment-related adverse events

From: Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

 

Grade 1

Grade 2

Grade 3

Grade 4

Fever

6 (30.0%)

0

0

0

Fatigue

10 (50.0%)

0

0

0

Headache

3 (15.0%)

0

0

0

Ostealgia

4 (20.0%)

0

0

0

Skin rash

2 (10.0%)

0

0

0

Pruritus

2 (10.0%)

0

0

0

Elevation in ALT

0

1 (5.0%)

1 (5.0%)

0

Elevation in AST

0

1 (5.0%)

1 (5.0%)

0

Decreased appetite

2 (10.0%)

0

0

0

Nausea

2 (10.0%)

   

Diarrhea

2 (10.0%)

0

0

0

Cough

1 (10.0%)

0

0

0

Vomiting

1 (10.0%)

0

0

0

Chest pain

0

1 (5.0%)

0

0

Hypothyroidism

0

1 (5.0%)

0

0

Heart failure

0

1 (5.0%)

1 (5.0%)

0

  1. ALT alanine aminotransferase, AST aspartate aminotransferase